Lynx1 Capital Management LP
SEC CIK 1910456 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KRRO | Korro Bio, Inc. | 10% | 1.54M | $84.3K | — | 2 | 2026-03-31 | 2026-08-06 |
| PASG | Passage BIO, Inc. | 10% | 673.8K | $1.47M | — | 4 | 2024-11-25 | 2026-06-25 |
| TCRX | TScan Therapeutics, Inc. | 10% | 8.01M | $3.25M | $63.9K | 3 | 2023-05-31 | 2025-12-19 |
| NEUP | Neuphoria Therapeutics Inc. | 10% | 875.3K | $3.29M | — | 1 | 2025-10-21 | 2025-10-21 |
| CGEM | Cullinan Therapeutics, Inc. | 10% | 8.56M | $11.93M | — | 2 | 2025-10-08 | 2025-10-14 |
Most active insiders at KRRO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | FORMELA JEAN FRANCOIS | Dir | — | $5.16M |
| 2 | Yang Rick | 10% | $2.30M | — |
| 3 | New Enterprise Associates 17, L.P. | 10% | $2.30M | — |
| 4 | Chang Carmen | 10% | $2.30M | — |
| 5 | Makhzoumi Mohamad | 10% | $2.30M | — |
| 6 | Florence Anthony A. Jr. | 10% | $2.30M | — |
| 7 | Walker Paul Edward | 10% | $2.30M | — |
| 8 | Mathers Edward T | 10% | $2.30M | — |
| 9 | BASKETT FOREST | 10% | $2.30M | — |
| 10 | SANDELL SCOTT D | 10% | $2.30M | — |
| 13 | Lynx1 Capital Management LP | 10% | $84.3K | — |
Transactions 12
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-08-13 09:54 | 2026-08-06+ | KRRO | Korro Bio, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $11.79 | +6,684 | 1.54M | +0.4% | +$78.8K |
| I | 2026-06-29 16:30 | 2026-06-25 | PASG | Passage BIO, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $4.12 | +50.1K | 673.8K | +8% | +$206.1K |
| I | 2026-04-02 12:00 | 2026-03-31 | KRRO | Korro Bio, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $10.60 | +520 | 1.54M | +0.0% | +$5,512 |
| MI | 2025-12-23 | 2025-12-19+ | TCRX | TScan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $0.9 | +161.8K | 8.01M | +2% | +$145.6K |
| I | 2025-10-23 | 2025-10-21 | NEUP | Neuphoria Therapeutics Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $5.14 | +639.1K | 875.3K | +271% | +$3.29M |
| MI | 2025-10-21 | 2025-10-14+ | CGEM | Cullinan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $8.46 | +248.7K | 8.56M | +3% | +$2.10M |
| MI | 2025-10-10 | 2025-10-08+ | CGEM | Cullinan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $6.73 | +1.46M | 8.55M | +21% | +$9.83M |
| MI | 2025-07-24 | 2025-07-22+ | PASG | Passage BIO, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $5.69 | +128.8K | 525.3K | +33% | +$733.7K |
| MI | 2025-05-21 | 2025-05-19+ | TCRX | TScan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $1.20 | +2.59M | 6.75M | +62% | +$3.11M |
| I | 2024-12-31 | 2024-12-27 | PASG | Passage BIO, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $0.65 | +373.6K | 9.26M | +4% | +$242.9K |
| MI | 2024-11-27 | 2024-11-25+ | PASG | Passage BIO, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $0.622 | +456.4K | 8.85M | +5% | +$283.8K |
| MI | 2023-06-02 | 2023-05-31 | TCRX | TScan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | S - Sale | $2.52 | -25.4K | 5.22M | -0.5% | -$63.9K |
Purchase Sale Sale after option exercise All abbreviations